As Cerulean continues to grow and advance our technologies and programs, we are committed to clear and consistent communication to our external audiences. Here we feature current and historic information concerning our technology, our pipeline and our corporate goals and achievements. Please check in often for the most recent press releases and news coverage.

08.27.10 :: Boston Globe
Cerulean encouraged by early data.
Cerulean Pharma Inc., a Cambridge company that seeks to design and develop nanopharmaceuticals, said it is encouraged by results of early clinical test for its lead drug candidate, CRLX101, which has the potential to treat a common form of lung cancer.
View Full Article

08.25.10 :: Cerulean Pharma Inc. Presents Data on Nanopharmaceutical Development Candidates and Platform Technologies at American Chemical Society National Meeting & Exposition.
View Press Release

08.19.10 :: Cerulean Pharma Inc. to Convene Nanomedicine Pioneers at 2010 American Chemical Society (ACS) National Meeting & Exposition in Boston.
View Press Release

03.29.10 :: Boston Globe
What's up with nanotech? Ultrasmall wonders are opening big new frontiers, despite fading of the initial excitement.
View Full Article

03.24.10 :: Scientific American
Thinking Outside of the Toy Box: 4 Children's Gizmos That Inspired Scientific Breakthroughs. Brilliant minds reach back to childhood to help them develop tiny transistors, study particle separation, make microfluidics devices, and fight cancer
View Full Article

03.29.10 :: Forbes Video Network
Fighting Cancer With Nanoparticals; Interview with Oliver Fetzer, President & CEO Cerulean Pharma Inc.
View Video

03.10.10 :: Cerulean Pharma Inc. Appoints Two Senior Executives to Management Team - Company Appoints John Ryan, Ph.D., M.D., to serve as Senior Vice President, Chief Medical Officer, and Karen Roberts to serve as Senior Vice President, Finance and Administration.
View Press Release

07.28.09 :: Cerulean Pharma Inc. Closes $10 Million Series B-1 Financing - Company Appoints Acting Chief Medical Officer, John Ryan, to advance clinical trial with lead nanopharmaceutical product candidate.
View Press Release

06.23.09 :: Cerulean Pharma Inc. Announces License Agreement with Calando Pharmaceuticals, Inc., a Subsidiary of Arrowhead Research Corporation
View Press Release

04.08.09 :: Cerulean Pharma Inc. Announces Appointment of Oliver S. Fetzer as
President and Chief Executive Officer
View Press Release

01.23.09 :: Sandra Glucksmann Named 2009 Mass High Tech Woman to Watch
View Press Release

10.24.08 :: Tempo Pharmaceuticals, Inc. Announces Name Change to Cerulean
Pharma Inc.
View Press Release

01.03.08 :: Tempo Pharmaceuticals Closes $8 Million in Series B Funding
View Press Release

05.23.07 :: Tempo Pharmaceuticals Closes $12.1 Million in Series A Funding
View Press Release